Glycosuria

TheracosBio and SmithRx Collaborate to Offer Newly Approved Diabetes Drug Brenzavvy™ (bexagliflozin) to Members with Type 2 Diabetes

Retrieved on: 
Jeudi, août 17, 2023
Software, Biotechnology, Pharmaceutical, Health, Diabetes, Data Management, Health Technology, Technology, Diabetic neuropathy, Type 2 diabetes, Tenderness, Glycosuria, Dialysis, Gangrene, Pain, Urinary tract infection, 1946 Antarctica PBM Mariner crash, Incidence, Patient, Risk, PBM, Insulin, Ulcer, Pancreatitis, Diet, Cardiovascular disease, Urination, Vomiting, Cost Plus Drugs, Hypoglycemia, FDA, Death, Exercise, World Market (store), Chronic kidney disease, Amputation, Creatinine, Hypotension, Dehydration, Metabolic acidosis, Fever, CVD, Osteomyelitis, History, Abdominal pain, Ischemia, Erythema, Swelling, Type, Moyamoya disease, Knee, Infection, Pyelonephritis, Elijah Cummings Lower Drug Costs Now Act, Partnership, Hospital, Necrotizing fasciitis, Diabetic ketoacidosis, Pharmacy, Perineum, SGLT2, Ketoacidosis, Acute kidney injury, Frenz, Nausea, Female, Pharmaceutical industry, Dietary supplement, Medical imaging, Meat

Working with TheracosBio and Cost Plus Drugs, SmithRx now provides BRENZAVVY as an option following its launch in July 2023.

Key Points: 
  • Working with TheracosBio and Cost Plus Drugs, SmithRx now provides BRENZAVVY as an option following its launch in July 2023.
  • BRENZAVVY is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
  • Diabetes is the most expensive chronic condition in the U.S. and accounts for 1 of every 4 dollars spent on healthcare.
  • In patients with type 1 diabetes mellitus, BRENZAVVY significantly increases the risk of diabetic ketoacidosis, a life-threatening event, beyond background rate.

FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis

Retrieved on: 
Mardi, septembre 21, 2021
Tablet, Food, Therapy, Miliaria, Rosacea, Irritation, Steroid, Hyperglycemia, Prevalence, BurNIng, Compliance, Itch, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Torso, FDA, Patient, Adolescence, Folliculitis, Body surface area, Scalp, Adult, Allergic contact dermatitis, Doxycycline, Immune system, Hypopigmentation, Glycosuria, Phase, CEO, Telangiectasia, Company, Ageing, Acne, Greasy hair, Dry, Hospira, ASX, Risk, Cushing's syndrome, Perioral dermatitis, Dermatology, Atrophy, Cell, Safety, Infection, Glaucoma, National Psoriasis Foundation, Ulobetasol, HPA, Time, Skin, Pharmaceutical industry, Cosmetics, Generic drug

LEXETTE, a super potent topical corticosteroid,is now approved for the treatment of plaque psoriasis in patients aged 12 years and older.

Key Points: 
  • LEXETTE, a super potent topical corticosteroid,is now approved for the treatment of plaque psoriasis in patients aged 12 years and older.
  • The FDA approved LEXETTE in 2018 based on evidence from two multicentre, randomized, double-blind, vehicle-controlled studies (n=560) in patients with plaque psoriasis involving between 2% to 12% body surface area.
  • LEXETTE (halobetasol propionate) foam is a potent corticosteroid indicated for the topical treatment of plaque psoriasis in patients twelve years of age and older.
  • LEXETTE foam was evaluated for the treatment of moderate to severe plaque psoriasis in two multicentre, randomised, double-blind, vehicle-controlled studies.